BeiGene and MEI Pharma to Test Drug Combination Therapy in B-Cell Malignancies
publication date: Oct 11, 2018
BeiGene will collaborate with MEI Pharma of San Diego to test MEI's ME-401, a PI3K delta inhibitor, in combination with BeiGene's BTK inhibitor in patients with B-cell malignancies. MEI will amend its ongoing Phase Ib trial to include evaluation of zanubrutinib, BeiGene's BTK inhibitor, in combination with ME-401 in B-cell malignancy patients. The costs of the trial will be shared equally by the two companies; both will supply clinical supplies of their respective candidates; and each company will retain full commercial rights to their own product. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: MEIP)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.